Impact of Patent Expirations on Generic Drug Competition

Patent expirations signify the end of exclusive rights for drug manufacturers, opening the door for generic competition. Notable examples include:

• Humira (adalimumab): With its patent expired, biosimilars have entered the market, significantly impacting prices.

• Revlimid (lenalidomide): The expiration of its patent in early 2024 has led to increased competition from generics.

• Eliquis (apixaban): Generic versions have emerged following its patent expiration in late 2023.

These changes have led to more affordable medication options, spurred innovation, and increased patient access to essential drugs.

Biotech Innovations: Patenting Gene Editing and Personalized Medicine

While patents expire, new technologies are reshaping the biotech landscape. CRISPR, a revolutionary gene-editing technology, and advancements in personalized medicine are at the forefront of innovation.

Gene Editing with CRISPR

CRISPR has transformed gene editing, with over 4,000 patents filed globally. Key players like the Broad Institute and UC Berkeley hold crucial patents, highlighting the competitive nature of this field.

Personalized Medicine

Personalized medicine, which tailors treatments based on individual genetic profiles, is witnessing significant patent activity. Innovations in biomarker discovery and pharmacogenomics are leading to more effective and personalized healthcare solutions.

Balancing Innovation and Access

The challenge lies in balancing the drive for innovation with the need for broader access to these technologies. Strategies like patent pools and compulsory licensing can help ensure that groundbreaking advancements benefit a wider population.

​As the pharmaceutical and biotech sectors evolve, a strategic approach fostering innovation and equitable access is essential for continued progress and global health improvement.